Dicerna on Novo's billion-dollar acquisition: Alleged wrongdoing has no hold in reality

US-based biotech firm Dicerna is distancing itself from the suits filed by its shareholders, following the announcement of Novo Nordisk's planned acquisition of the firm.

Photo: Novo Nordisk / PR

Claims of alleged wrongdoing have no hold in reality, says Dicerna in a filing sent to the US Securities and Exchange Commission.
This stance has been taken by Dicerna after some shareholders have filed suits against the firm, alleging violations of the US Securities Exchange Act.

"The company, parent and purchaser believe the claims asserted in each of the complaints are without merit," the document reads.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs